Influenza, Human  >>  PREVNAR 13 (pneumococcal 13-valent conjugate vaccine)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
NCT02215863: Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years

Completed
4
1195
RoW
Fluad and Prevenar13, Fluad, Prevenar13
Korea University Guro Hospital, Pfizer
Influenza, Streptococcus Pneumoniae
03/15
03/15
NCT02124161: Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.

Completed
4
882
US
13-valent pneumococcal conjugate vaccine, 13vPnC, Seasonal Inactivated Influenza Vaccine, SIIV, Placebo
Pfizer
PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE
05/15
05/15

Download Options